Holen Sie sich die Stockscreener-App
12.52
0.64%
0.08
Vorhandelsmarkt:
11.80
-0.72
-5.75%
Schlusskurs vom Vortag:
$12.44
Offen:
$12.48
24-Stunden-Volumen:
167.10K
Relative Volume:
1.82
Marktkapitalisierung:
$292.14M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-246.41M
KGV:
-0.9829
EPS:
-12.7377
Netto-Cashflow:
$-134.42M
1W Leistung:
-5.30%
1M Leistung:
-30.13%
6M Leistung:
-60.96%
1J Leistung:
+29.07%
1-Tages-Spanne:
$12.30
$13.02
1-Wochen-Bereich:
$12.03
$14.14
52-Wochen-Spanne:
$8.46
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
12.52 | 316.18M | 31,000 | -246.41M | -134.42M | -12.74 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Needham | Buy |
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock - Investing.com India
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com - Investing.com South Africa
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares By Investing.com - Investing.com India
Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock - Investing.com UK
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares - Investing.com UK
Lyell Immunopharma (LYEL) CEO’s 388-share tax-related stock sale detailed in Form 4 - Stock Titan
Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares - Stock Titan
Lyell Immunopharma (LYEL) COO’s 89-share sale tied to RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting - TipRanks
Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections - Stock Titan
Citizens upgrades Lyell Immunopharma stock price target on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL) - Seeking Alpha
Lyell Immunopharma issues colorectal cancer drug safety update - MSN
Director at Lyell Immunopharma (LYEL) receives new option grant - Stock Titan
[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity - Stock Titan
Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director granted 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250-share option grant - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250 options at $13.22 strike - Stock Titan
Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22 - Stock Titan
Lyell reports safety data for ronde-cel in lymphoma trial By Investing.com - Investing.com Canada
Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma - TradingView
New Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell Immunopharma - Quiver Quantitative
Over 100 lymphoma patients get CAR-T with no Grade 3+ CRS - Stock Titan
Lyell Immunopharma (LYEL) CMO logs small tax-driven stock sale on Form 4 - Stock Titan
LYEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
H.C. Wainwright reiterates Lyell Immunopharma stock rating on safety data By Investing.com - Investing.com Canada
Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Citizens upgrades Lyell Immunopharma stock rating on safety data By Investing.com - Investing.com Canada
Lyell Immunopharma amends LYL273 Phase 1 trial to Phase 1/2 - grafa.com
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update - Benzinga
Lyell Immunopharma stock rises on trial amendment - Investing.com UK
Lyell Immunopharma stock rises on trial amendment By Investing.com - Investing.com Canada
Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study - Moomoo
Lyell Immunopharma Reports Significant Reduction in Grade ≥ 2 Diarrhea/Colitis in Phase 1 Trial of LYL273 for Metastatic Colorectal Cancer with GI Prophylaxis - Quiver Quantitative
Lyell Immunopharma Provides Update on Safety Profile of - GlobeNewswire
New regimen cuts gut side effects in Lyell's LYL273 colon cancer trial - Stock Titan
Lyell Immunopharma, Inc.Common Stock (NQ: LYEL - FinancialContent
Lyell to present ronde-cel lymphoma trial data at EHA congress - Investing.com Australia
Lyell Immunopharma to Present Phase 1/2 Ronde-Cel Safety and Translational Data in Large B-Cell Lymphoma at EHA 2026Profit Recovery Report - newsline.com
Lyell to present ronde-cel lymphoma trial data at EHA congress By Investing.com - Investing.com South Africa
Lyell Immunopharma to Present Phase 1/2 Clinical Trial Data on Rondecabtagene Autoleucel at EHA 2026 Congress - Quiver Quantitative
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress - GlobeNewswire
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Lyell Immunopharma, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 150% Upside - TradingView
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
Lyell Immunopharma Q1 2026 Earnings: EPS Beats Estimates by 54.4% as Stock Declines 13.18% - newsline.com
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Lyell Quiet as Bigger CAR-T Question Lingers for Investors - Bez Kabli
Lyell Immunopharma (LYEL) Holds Steady With Modest Gains Amid Technical ConsolidationFactor ETF Flow - newsline.com
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lyell Immunopharma Inc-Aktie (LYEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lee Gary K. | Chief Scientific Officer |
May 11 '26 |
Sale |
18.92 |
130 |
2,460 |
17,808 |
| Hill Stephen J. | Chief Operating Officer |
May 11 '26 |
Sale |
18.92 |
89 |
1,684 |
17,894 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
May 11 '26 |
Sale |
18.91 |
217 |
4,103 |
15,420 |
| Shook David | Chief Medical Officer |
Jun 10 '26 |
Sale |
12.64 |
1,977 |
24,989 |
20,923 |
| ARCH Venture Partners IX, LLC | 10% Owner |
Mar 06 '26 |
Buy |
25.61 |
488,090 |
12,499,985 |
1,426,528 |
| ARCH Venture Fund XIII, L.P. | 10% Owner |
Mar 06 '26 |
Buy |
25.61 |
488,090 |
12,499,985 |
1,426,528 |
| Seely Lynn | President and CEO |
Feb 11 '26 |
Sale |
23.39 |
7,455 |
174,372 |
74,266 |
| Hill Stephen J. | Chief Operating Officer |
Feb 11 '26 |
Sale |
23.39 |
1,236 |
28,910 |
17,795 |
| Lee Gary K. | Chief Scientific Officer |
Feb 11 '26 |
Sale |
23.39 |
1,671 |
39,085 |
16,938 |
| Hill Stephen J. | Chief Operating Officer |
Feb 10 '26 |
Sale |
23.12 |
109 |
2,520 |
19,031 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):